Q-omics provides the consensus-scored MAP3K1 profile across patient tissues and cancer cell-line models. MAP3K1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAP3K1 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, MAP3K1 RNA expression shows 20,553 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where MAP3K1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K1 survival associations across molecular data types. MAP3K1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K1 RNA expression–survival associations across cancer types. High MAP3K1 expression shows unfavorable associations in LGG and LIHC, but favorable associations in KIRC, HNSC, LAML and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAP3K1 RNA expression.
This table summarizes MAP3K1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MAP3K1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K1 shows lower tumor expression in KICH and higher tumor expression in LIHC, THCA, BLCA, KIRP and STAD. The LIHC box plot shows higher MAP3K1 RNA expression in tumor versus normal tissue (log2 FC = +1.123, t-test p < 0.001).
This table shows molecular features associated with MAP3K1 in patient tissues and cancer cell lines. In patient samples, MAP3K1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP3K1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
